Prices delayed by at least 15 minutes | Print
Chemomab Therapeutics Ltd (CMMB)
American Depository ReceiptThis share can be held in a Dealing account
Company profile
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Chemomab Therapeutics Ltd First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
| Chemomab Therapeutics Ltd Annual Report for 2024 | 2025-03-28T00:00:00 |
| Chemomab Therapeutics Ltd Fourth Quarter Earnings Results for 2024 | 2025-03-07T00:00:00 |
| Chemomab Therapeutics Ltd Third Quarter Earnings Results for 2024 | 2024-11-29T00:00:00 |
| Chemomab Therapeutics Ltd Second Quarter Earnings Conference Call for 2024 | 2024-08-31T08:00:00 |
| Chemomab Therapeutics Ltd Second Quarter Earnings Result for 2024 | 2024-08-31T00:00:00 |
| Chemomab Therapeutics Ltd Annual General Meeting for 2024 | 2024-05-20T00:00:00 |
| Chemomab Therapeutics Ltd First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
| Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference | 2024-05-07T09:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Chemomab Therapeutics Ltd Annual General Meeting for 2024 | 2024-05-20T00:00:00 |
| Chemomab Therapeutics Ltd First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
| Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference | 2024-05-07T09:00:00 |
| Chemomab Therapeutics Ltd Annual Report for 2023 | 2024-03-28T00:00:00 |
| Leerink Partners Global BioPharma Conference | 2024-03-12T10:40:00 |
| Chemomab Therapeutics Ltd Fourth Quarter Earnings Results for 2023 | 2024-03-07T00:00:00 |
| Chemomab Therapeutics to Participate in Upcoming Investor Conferences | 2024-02-14T08:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.